Since being introduced in the 1940s, cervical cytology – despite its limitations – has had
unequivocal success in reducing cervical cancer burden in many countries. However, we now …

Objective Previous findings from cross-sectional studies have shown human papillomavirus
(HPV) testing to be more sensitive than cytology testing for primary cervical screening. This …

Substantial evidence exists to support the introduction of molecular testing for human
papillomavirus (HPV) as the primary technology in cervical cancer screening. While HPV testing is …

Background Although women with endometrial cancer generally have a favourable prognosis,
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …

Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO
and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and …

A rapidly increasing body of evidence links human papillomavirus (HPV) to cervical
neoplasia through epidemiologic associations, pathologic features, molecular detection, and …

AIM: The impact of PTEN status and microsatellite instability (MSI) on the prognosis of women
with endometrial cancer is controversial. The aim of this study was to investigate MSI and …

Objective To develop guidelines to inform the Ontario Cervical Screening Program’s invitations
to women in the target population, provide evidence-based clinical practice guidance for …

Objective: To develop evidence-based consensus recommendations on the delivery of cervical
cancer screening, human papillomavirus (HPV) education, HPV testing, and the optimal …

BACKGROUND ThinPrep (TP) cytology for evaluation of nongynecological specimens is being
increasingly used. There are few studies comparing TP with conventional smears (CS) in …